---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-062042"
form_type: "8-K"
ticker: "ELVN"
cik: "0001672619"
company_name: "Enliven Therapeutics, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:57:32.930113+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Enliven Therapeutics Q3 net loss $20.8M; cash $263.5M; ELVN-001/002 data on track for 2024

## Summary
- Cash, cash equivalents and marketable securities of $263.5M as of Sept 30, 2023; expected runway into early 2026.
- Net loss $20.8M vs $10.6M in Q3 2022; R&D expense $19.6M (up from $7.8M); G&A $4.6M (up from $3.1M).
- ELVN-001 (CML) and ELVN-002 (HER2-altered solid tumors) Phase 1 trials enrolling; initial proof-of-concept data expected in 2024.
- Third IND-enabling study completed; additional pipeline details and guidance planned for H1 2024.

## SEC filing metadata
- accession: 0000950170-23-062042
- form_type: 8-K
- ticker: ELVN
- cik: 0001672619
- company_name: Enliven Therapeutics, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000095017023062042/0000950170-23-062042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000095017023062042/elvn-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-062042
- JSON: https://secwatch.observer/filing/0000950170-23-062042.json
- Plain text: https://secwatch.observer/filing/0000950170-23-062042.txt

## Key facts
- Earnings Releases
  Enliven Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: net income $20.8 million.
  - Period: the third quarter ended September 30, 2023
  - Net income: $20.8 million
  - Result: reported results
  source text: Enliven reported a net loss of $20.8 million for the third quarter of 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1672619/000095017023062042/0000950170-23-062042-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.